Education
About Us
Working with TipRanks
Follow Us
Mayne Pharma Group (AU:MYX)
ASX:MYX
Total Valuation
Mayne Pharma Group has a market cap or net worth of $465.54M. The enterprise value is ―.
Market Cap$465.54M
Enterprise Value―
Share Statistics
Mayne Pharma Group has 81,245,830 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding81,245,830
Owned by Insiders0.07%
Owned by Institutions<0.01%
Financial Efficiency
Mayne Pharma Group’s return on equity (ROE) is -0.38 and return on invested capital (ROIC) is -4.88%.
Return on Equity (ROE)-0.38
Return on Assets (ROA)-0.15
Return on Invested Capital (ROIC)-4.88%
Return on Capital Employed (ROCE)-0.06
Revenue Per Employee456.65K
Profits Per Employee-198.38K
Employee Count850
Asset Turnover0.34
Inventory Turnover2.27
Valuation Ratios
The current PE Ratio of Mayne Pharma Group is -2.12. Mayne Pharma Group’s PEG ratio is -0.18.
PE Ratio-2.12
PS Ratio0.00
PB Ratio1.64
Price to Fair Value0.81
Price to FCF-52.22
Price to Operating Cash Flow1.87K
PEG Ratio-0.18
Income Statement
In the last 12 months, Mayne Pharma Group had revenue of 388.15M and earned -174.23M in profits. Earnings per share was -2.19.
Revenue388.15M
Gross Profit218.53M
Operating Income-45.86M
Pretax Income-190.09M
Net Income-174.23M
EBITDA-116.93M
Earnings Per Share (EPS)-2.19
Cash Flow
In the last 12 months, operating cash flow was 391.00K and capital expenditures -11.65M, giving a free cash flow of -11.26M billion.
Operating Cash Flow391.00K
Free Cash Flow-11.26M
Free Cash Flow per Share-0.14
Dividends & Yields
Mayne Pharma Group pays an annual dividend of AU$0.027, resulting in a dividend yield of ―
Dividend Per ShareAU$0.027
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.25
52-Week Price Change-2.67%
50-Day Moving Average7.07
200-Day Moving Average5.36
Relative Strength Index (RSI)34.27
Average Volume (3m)703.79K
Important Dates
Mayne Pharma Group upcoming earnings date is Aug 21, 2025, TBA Not Confirmed.
Last Earnings DateFeb 25, 2025
Next Earnings DateAug 21, 2025
Ex-Dividend DateJan 18, 2023
Financial Position
Mayne Pharma Group as a current ratio of 1.47, with Debt / Equity ratio of 8.93%
Current Ratio1.47
Quick Ratio1.23
Debt to Market Cap0.09
Net Debt to EBITDA0.61
Interest Coverage Ratio-1.33
Taxes
In the past 12 months, Mayne Pharma Group has paid -21.47M in taxes.
Income Tax-21.47M
Effective Tax Rate0.11
Enterprise Valuation
Mayne Pharma Group EV to EBITDA ratio is -2.55, with an EV/FCF ratio of -8.25.
EV to Sales0.77
EV to EBITDA-2.55
EV to Free Cash Flow-8.25
EV to Operating Cash Flow-19.49
Balance Sheet
Mayne Pharma Group has $124.91M in cash and marketable securities with AU$39.87M in debt, giving a net cash position of -$85.05M billion.
Cash & Marketable Securities$124.91M
Total DebtAU$39.87M
Net Cash-$85.05M
Net Cash Per Share-$1.05
Tangible Book Value Per Share-$1.44
Margins
Gross margin is 58.97%, with operating margin of -11.81%, and net profit margin of -44.89%.
Gross Margin58.97%
Operating Margin-11.81%
Pretax Margin-48.97%
Net Profit Margin-44.89%
EBITDA Margin-30.12%
EBIT Margin-40.08%
Analyst Forecast
The average price target for Mayne Pharma Group is $7.40, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$7.40
Price Target Upside19.32% Upside
Analyst ConsensusHold
Analyst Count2
Revenue Growth Forecast52.96%
EPS Growth Forecast45.68%